EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Berbamine sensitizes hepatocellular carcinoma to chemotherapy by inhibiting autophagy via modulating SIRT1-mediated acetylation

Qin Peng, Ling Xiao, Xinhui Huang, Ziyuan Huang, Guangxian Zhang, Jihong Zhou, Yuhui Tan

Frontiers in Pharmacology · 14.05.2026 · 17

DOI: 10.3389/fphar.2026.1763828 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 14.05.2026. Verfasst von Qin Peng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen Bao'an Traditional Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Shenzhen, China. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemoresistance driven by pro-survival autophagy remains a major obstacle in hepatocellular carcinoma (HCC) treatment. Berbamine (BBM), a natural alkaloid with a favorable clinical safety profile, shows potential as an autophagy inhibitor, yet its precise mechanism in HCC remains unclear. Using CCK-8, colony formation, and apoptosis assays, we first demonstrated that BBM synergistically enhanced the efficacy of multiple chemotherapeutic agents (5-FU, Sorafenib, Paclitaxel) against HCC cells in vitro . This synergistic effect was confirmed in an H22 xenograft mouse model in vivo . To investigate the mechanism, we monitored autophagic flux and lysosomal function. Western blot and immunofluorescence analyses revealed that BBM treatment led to the concurrent accumulation of LC3-II and p62, indicating a blockade of late-stage autophagic flux. Further experiments, including LysoTracker staining and assessment of lysosomal protease levels, showed that BBM impaired both autophagosome-lysosome fusion and lysosomal acidification. Mechanistically, we found that BBM downregulated SIRT1 protein expression and reduced the intracellular NAD + /NADH ratio, thereby inhibiting SIRT1 deacetylase activity. This suppression impaired the nuclear translocation and function of the key autophagy transcription factor TFEB, leading to decreased levels of its downstream targets RAB7, CTSB, and CTSD. Crucially, rescue experiments using specific agonists revealed that SIRT1 activation completely reversed all BBM-induced effects, including autophagic flux blockade and downstream protein suppression, whereas TFEB activation only partially rescued the expression of RAB7, CTSB, and CTSD without restoring autophagic flux. This establishes SIRT1 as the primary upstream regulator in this pathway. Our study identifies BBM as a novel autophagy inhibitor that targets the SIRT1-TFEB axis to disrupt autolysosomal fusion and degradation, and nominates it as a promising combinational agent to overcome chemoresistance in HCC.

Schlagwörter

Stichwörter der Autor:innen

SIRT1TFEBautophagyberbaminechemosensitivityhepatocellular carcinoma

Autor:innen und Institutionen

  • Shenzhen Bao'an Traditional Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Shenzhen, China.
  • Research Center of Integrative Medicine, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Department of Biochemistry, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • School of Life Sciences and Technology, Tongji University, Shanghai, China.

Zitieren

APA

Peng, Q., Xiao, L., Huang, X., Huang, Z., Zhang, G., Zhou, J., & Tan, Y. (2026). Berbamine sensitizes hepatocellular carcinoma to chemotherapy by inhibiting autophagy via modulating SIRT1-mediated acetylation. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1763828

Vancouver

Peng Q, Xiao L, Huang X, Huang Z, Zhang G, Zhou J, et al. Berbamine sensitizes hepatocellular carcinoma to chemotherapy by inhibiting autophagy via modulating SIRT1-mediated acetylation. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1763828

BibTeX
@article{Peng2026,
  author = {Peng, Qin and Xiao, Ling and Huang, Xinhui and Huang, Ziyuan and Zhang, Guangxian and Zhou, Jihong and Tan, Yuhui},
  title = {Berbamine sensitizes hepatocellular carcinoma to chemotherapy by inhibiting autophagy via modulating SIRT1-mediated acetylation},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1763828}
}
Kostenlos starten →